Navigation Links
PRA International Experts to Speak at Industry Events
Date:3/23/2011

RALEIGH, N.C., March 23, 2011 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that two of our experts will be speakers at the upcoming Partnerships in Clinical Trials and Late Phase Drug Development conferences. PRA will also be exhibiting at both conferences.

Mike Hill, Project Manager for PRA's Late Phase Services group, will make a presentation at the Late Phase Drug Development conference in Boston, MA on 23 March at 11:10 AM EDT. Mr. Hill will discuss the application of statistics to post-marketing studies in his speech, "Utilizing Statistical Techniques to Drive Late Phase Operations". Attendees can learn more about our late phase and other services at our exhibition booth.

Mr. Hill has over six years of experience working with global registries and observational studies. He has designed and managed large-scale disease, drug and diagnostic registries across multiple therapeutic areas. PRA's Late Phase Services group supports global and regional post-approval studies with management locations centralized in our Horsham, Pennsylvania and Mannheim, Germany offices.

Kent Thoelke, Senior Vice President of PRA's Scientific and Medical Affairs group, will present at Partnerships in Clinical Trials being held in Phoenix, Arizona on 31 March at 2:15 PM PDT. He will discuss collaborative models that sponsors, CROs and investigative sites are pursuing to improve efficiencies and reduce costs in his session, "Strategic Sponsor-Site Partnership Models: Improving Site Selection and Recruiting in a Collaborative Environment". PRA representatives will also be available at Booth #1200 to discuss our experience in supporting clinical trials.

With over 19 years of experience in all aspects of global drug development, Mr. Thoelke has particular expertise in the execution of global studies. In his role at PRA, he provides scientific and strategic oversight of product development to support project teams and client development plans. PRA's Scientific and Medical Affairs team covers a broad range of therapeutic areas, providing support across all phases of drug development.

About PRA

PRA conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 39 global offices.

PRA's therapeutic expertise, global reach and project experience combined with its extensive local knowledge and differentiating philosophy—THE PERSONAL ELEMENT—enable its project teams to deliver consistent and on-time performance. This unique PRA philosophy recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to be innovative and to use their personal commitment to accelerate the development life cycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... 2016 , ... Southern Illinois University School of Dental Medicine ... State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host a ... , They expect to treat approximately 2,000 patients from Illinois, Missouri, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion research programs and ... enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. ...
Breaking Medicine News(10 mins):